Brdu Labeling Solution
Brdu Labeling Solution - Related Videos
12:46
Bromodeoxyuridine (BrdU) Labeling and Subsequent Fluorescence Activated Cell Sorting for Culture-independent Identification of Dissolved Organic Carbon-degrading Bacterioplankton
0 Views •
Cited by 6 •
2011
Environmental bacterioplankton are incubated with a model dissolved organic carbon (DOC) compound and a DNA labeling reagent, bromodeoxyuridine (BrdU). Afterward, DOC-degrading cells are separated from the bulk community based on their elevated BrdU incorporation using fluorescence activated cell sorting (FACS). These cells are then identified by subsequent molecular analyses.
03:24
BrdU Immunofluorescence Staining: A Technique to Identify Cells in Different Phases of Cell Cycle
0 Views •
2023
This video describes the protocol for BrdU immunofluorescence staining. The technique allows the identification of cells in different phases of cell cycle. Addition of DNA dyes and antibody labeling allows the detailed analysis of the fate of the S phase cells at later times.
09:14
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
0 Views •
Cited by 4 •
2016
In this protocol, we describe a novel BrdU-ChIP-Slot-Western technique to examine proteins and histone modifications associated with newly synthesized or nascent DNA.
06:44
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
0 Views •
Cited by 10 •
2021
In the present protocol, we demonstrate how to visualize DNA double-strand end resection during S/G2 phase of the cell cycle using an immunofluorescence-based method.
11:23
Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry
0 Views •
Cited by 13 •
2012
Tracking subtle changes in the progression and kinetics of cell cycle stages can be accomplished by use of a combination of metabolic labeling of nucleic acids with BrdU and total genomic DNA staining via Propidium Iodide. This method avoids the need of chemical synchronization of cycling cells, thereby preventing the introduction of non-specific DNA damage, which in turn affects cell cycle progression.
FAQs
Because incorporation occurs during S phase, BrdU labeling provides a time-linked readout of DNA synthesis rather than a general measure of all cells. The number or proportion of cells with labeled DNA indicates how actively a population is entering or progressing through the cell cycle. In cancer studies, this helps identify tumors or cultures with relatively high proliferative activity.
The detection stage relies on exposing incorporated BrdU and then using anti-BrdU antibodies to recognize it. DNA denaturation is often performed before antibody application, making the labeled DNA accessible for immunological detection. This pairing connects the molecular label to a measurable signal, allowing investigators to quantify cells that synthesized DNA during the labeling period.
Treatment-related changes in BrdU detection can indicate that a therapy has altered cancer-cell DNA synthesis and cell-cycle activity. A reduced labeling outcome is consistent with less proliferative activity, whereas maintained or increased labeling suggests that DNA synthesis remains active under the tested conditions. This makes the approach useful for evaluating drug response and treatment effects on tumor cells.
BrdU labeling focuses on the activity of cells synthesizing DNA, providing a cellular view of proliferation within a cancer model. Tumor-growth assessment describes an overall outcome, while labeling can help indicate whether changes are associated with altered cell-cycle activity. Used together, these measurements support a more detailed interpretation of tumor biology and growth behavior.
A typical workflow introduces the labeling solution to the cells or cancer model, allowing BrdU to be incorporated into DNA during S phase. The labeled DNA is then prepared for detection, often through denaturation, followed by anti-BrdU antibody-based recognition. Researchers quantify the detected labeling to estimate proliferative activity and compare conditions such as treated and untreated samples.
Researchers can apply this method when they need to measure proliferation in tumor cells, examine tumor growth, or evaluate how a cancer therapy changes cell-cycle activity. It is also relevant to studies of tumor biology and the mechanisms controlling cancer-cell proliferation. The resulting measurements can connect treatment conditions with changes in DNA synthesis and proliferative behavior.
By identifying cells that synthesized DNA, BrdU labeling helps investigators examine the proliferative component of tumor biology. Comparisons across cancer models or experimental conditions can show whether cell-cycle activity changes in association with a treatment or other study variable. This evidence contributes to analyses of how proliferation is regulated and how those mechanisms relate to cancer progression or drug response.